ATE320255T1 - Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen - Google Patents

Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen

Info

Publication number
ATE320255T1
ATE320255T1 AT02720814T AT02720814T ATE320255T1 AT E320255 T1 ATE320255 T1 AT E320255T1 AT 02720814 T AT02720814 T AT 02720814T AT 02720814 T AT02720814 T AT 02720814T AT E320255 T1 ATE320255 T1 AT E320255T1
Authority
AT
Austria
Prior art keywords
treatment
kinase inhibitors
tie2 receptor
receptor kinase
angiogenic diseases
Prior art date
Application number
AT02720814T
Other languages
English (en)
Inventor
Marcus A Semones
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE320255T1 publication Critical patent/ATE320255T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT02720814T 2001-01-19 2002-01-18 Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen ATE320255T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26286201P 2001-01-19 2001-01-19

Publications (1)

Publication Number Publication Date
ATE320255T1 true ATE320255T1 (de) 2006-04-15

Family

ID=22999379

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02720814T ATE320255T1 (de) 2001-01-19 2002-01-18 Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen

Country Status (8)

Country Link
US (1) US7005434B2 (de)
EP (1) EP1372648B1 (de)
JP (1) JP2004521118A (de)
AT (1) ATE320255T1 (de)
AU (1) AU2002251788A1 (de)
DE (1) DE60209886T2 (de)
ES (1) ES2259079T3 (de)
WO (1) WO2002060382A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
EP1799194B1 (de) 2004-09-24 2011-11-16 Boehringer Ingelheim Pharmaceuticals Inc. Neue klasse von surfuctantähnlichen materialien mit vitamin-e-tpgs und wasserlöslichem polymer
WO2006066071A2 (en) * 2004-12-17 2006-06-22 Mayo Foundation For Medical Education And Research Prognosis of renal cell carcinoma
CA2593718A1 (en) * 2004-12-31 2007-05-31 Gpc Biotech Ag Napthyridine compounds as rock inhibitors
EP1917245A1 (de) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
US20070049592A1 (en) * 2005-08-22 2007-03-01 Geuns-Meyer Stephanie D Bis-aryl urea compounds and methods of use
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025489A (en) 1989-11-17 2000-02-15 Schering Aktiengesellschaft Tricyclic pteridinones and a process for their preparation
DE69515898T2 (de) * 1994-11-14 2000-08-17 Warner Lambert Co 6-ARYL-PYRIDO[2,3-d]PYRIMIDINE UND -NAPHTHYRIDINE ZUR HEMMUNG DER DURCH PROTEIN-TYROSIN-KINASE HERVORGERUFENEN ZELLVERMEHRUNG
GB9605437D0 (en) 1996-03-15 1996-05-15 Iaf Biochem Int Cytomegalovirus inhibiting compounds
US5945431A (en) * 1996-03-15 1999-08-31 Biochem Therapeutics Incorporated Cytomegalovirus inhibiting compounds
US6150359A (en) 1997-08-20 2000-11-21 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
CA2314408A1 (en) * 1997-12-11 1999-06-17 Biochem Pharma Inc. Antiviral compounds
CN1138778C (zh) 1998-05-26 2004-02-18 沃尼尔·朗伯公司 用作细胞增殖抑制剂的二环嘧啶及二环3,4-二氢嘧啶化合物及用途

Also Published As

Publication number Publication date
JP2004521118A (ja) 2004-07-15
WO2002060382A3 (en) 2002-09-26
AU2002251788A1 (en) 2002-08-12
WO2002060382A2 (en) 2002-08-08
EP1372648B1 (de) 2006-03-15
EP1372648A4 (de) 2004-09-01
US20040048888A1 (en) 2004-03-11
DE60209886T2 (de) 2006-10-26
US7005434B2 (en) 2006-02-28
ES2259079T3 (es) 2006-09-16
EP1372648A2 (de) 2004-01-02
DE60209886D1 (de) 2006-05-11

Similar Documents

Publication Publication Date Title
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
DE69837809D1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
DE60119285D1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
DE60124791D1 (de) S-Methyl-Dihydro-Ziprasidone zur Behandlung von psychiatrischen Störungen.
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties